605507 國邦醫藥
按盤價 
20.990 +1.900 (+9.953%) | 2024/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 2,892,357 | 2.94% | 5,349,448 | 5,720,925 | 4,505,351 | 4,206,318 | |
| 減：營業總成本 | 2,397,206 | 0.90% | 4,654,821 | 4,664,769 | 3,665,391 | 3,269,523 | |
| 其中:營業成本 | 2,123,115 | 0.27% | 4,097,119 | 4,144,882 | 3,147,622 | 2,775,863 | |
| 財務費用 | (21,099) | -47.91% | (46,282) | (68,011) | 28,054 | 81,815 | |
| 資產減值損失 | (44,541) | 161.73% | (31,447) | (27,706) | (51,831) | (14,404) | |
| 公允價值變動收益 | 5,812 | 59.77% | 10,342 | 4,558 | 6,257 | 35 | |
| 投資收益 | 10,280 | -811.66% | 13,221 | 19,537 | 4,276 | 3,271 | |
| 其中：對聯營企業和合營企業的投資收益 | (453) | 57.78% | 60 | (745) | (1,561) | (1,326) | |
| 營業利潤 | 472,459 | 13.16% | 702,263 | 1,052,878 | 808,774 | 936,116 | |
| 利潤總額 | 464,089 | 12.40% | 697,649 | 1,035,639 | 806,782 | 943,437 | |
| 減：所得稅費用 | 59,720 | 6.55% | 87,670 | 115,017 | 100,552 | 133,149 | |
| 淨利潤 | 404,369 | 13.31% | 609,979 | 920,622 | 706,230 | 810,288 | |
| 減：非控股權益 | (229) | -62.74% | (2,485) | (282) | 199 | 288 | |
| 股東淨利潤 | 404,598 | 13.18% | 612,464 | 920,904 | 706,030 | 810,000 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.730 | 14.06% | 1.100 | 1.650 | 1.380 | 1.710 | |
| 每股派息 (元) * | -- | -- | 0.302 | 0.600 | 0.700 | -- | |
| 每股淨資產 (元) * | 13.547 | 5.48% | 13.299 | 12.804 | 11.356 | 6.890 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 30/09/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
